

Participate in this activity online anytime at www.cmeoutfitters.com/CMW439

Lung Cancer: Crossing the Barrier from Empiric to Molecular Therapy in Non-Small Cell Lung Cancer

Module 1: A Rapid Evolution in Advanced Non-Small-Cell Lung Cancer: Shifting the Paradigm to Individualized Therapy

Module 2: State of the Union on Molecular Therapies in Advanced Non-Small Cell Lung Cancer

Co-sponsored by Indiana University School of Medicine, and CME Outfitters, LLC.



EDITORIAL FACULTY

Nasser Hanna, MD

Associate Professor of Medicine
Indiana University School of Medicine
Indianapolis, IN

CME Outfitters and Indiana University School of Medicine acknowledge medical writer Theodore Bosworth for his primary contribution to the development of this continuing education activity.

Faculty Disclosure Statement: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

LEARNING OBJECTIVES

At the end of this CE activity, participants should be able to:

- Recognize the significance of histology and molecular traits in treatment selection for patients with lung cancer.
- List epidemiologic and clinical characteristics that differentiate lung cancer in smokers vs. never-smokers.
- Compare and contrast current and emerging therapies in the management of patients with lung cancer and translate that knowledge in to individualized care of patients.

CREDIT INFORMATION

CME Accreditation (Physicians): Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Indiana University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

CNE Credit (Nurses): This activity has been submitted to the New York State Nurses Association for approval to award contact hours. The New York State Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

1.0 contact hours will be awarded upon successful completion.

CPE Credit (Pharmacists): CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)

Universal Program Number: 376-999-10-005-H01-P
Activity Type: knowledge-based

CREDIT INSTRUCTIONS/ REQUIREMENTS

Successful completion of this CE activity includes reviewing the educational activity in its entirety, and following the instructions below:

To complete your credit request form, activity evaluation, and post-test online (70% pass rate required), and print your certificate or statement of credit immediately, please visit www.cmeoutfitters.com/test (requires free account activation).

Questions? Please call **877.CME.PROS**. Forms must be submitted by January 11, 2011. There is no fee for participation in this activity. The estimated time for completion of this activity is 60 minutes.

Release Date: January 11, 2010

Credit Expiration Date: January 11, 2011

This activity offers CE credit for:

- Physicians (CME)
- Nurses (CNE) – Pending
- Pharmacists (CPE)

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.

You can download this monograph at www.cmeoutfitters.com/CMW439.

For more information on this one-hour activity, call CME Outfitters at **877.CME.PROS**.

STATEMENT OF NEED

Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers.¹ Lung cancer represents the most common cancer-related cause of death in men and women. Survival rates for patients with NSCLC are dismal, with fewer than 15% alive at year two and less than 1% alive at year five.² Although often considered a preventable disease because of the relationship of lung malignancies to smoking, approximately 10% of cases occur in individuals who have never smoked. Emerging evidence from clinical studies indicates that lung tumors in these patients have been associated with a different phenotype and have a different molecular profile requiring individualized therapy. An increased understanding of the molecular and histologic basis of NSCLC has led to the identification of a number of suitable targets for treatment or chemoprevention of lung cancer. The goal of traditional therapies was to eradicate malignant cells. Emerging molecular therapies target the physiology of cancer and hold promise for better individual and combination therapies for advanced NSCLC to extend survival and preserve an acceptable quality of life. This two-part activity will explore the evolving understanding of NSCLC and report on emerging evidence for targeted, individualized treatment strategies.

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med* 2008;359:1367-1380.

2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;290:2149-2158.

ACTIVITY GOAL

To address knowledge gaps related to the significance of histologic and molecular targets in the development of individualized treatment strategies in patients with NSCLC.

TARGET AUDIENCE

Physicians (surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists), physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals interested in the care of patients with NSCLC.

ACKNOWLEDGEMENT OF FINANCIAL SUPPORT

The activity is supported by an unrestricted educational grant from Pfizer Inc.

FAX completed form to **240.243.1033**

YES! Register me for this evidence-based CME Outfitters activity.

Site Name: _____ # Participants: _____

Individual Name: _____ Degree: _____

Address: _____

City/State/ZIP: _____

Practice Setting: _____ Phone: _____

Fax: _____ Email: _____